What question did this study set out to answer?

To evaluate the effectiveness of lifileucel in patients with unresectable or metastatic melanoma.

April 23, 2026Open Access

Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Unresectable or Metastatic Melanoma

Key Points

To evaluate the effectiveness of lifileucel in patients with unresectable or metastatic melanoma.
Retrospective analysis of patient data from multiple centers
Focus on patients previously treated with immune checkpoint inhibitors
Assessment of lifileucel infusion outcomes
Preliminary findings suggest positive outcomes for lifileucel in advanced melanoma
Patients previously treated with immune therapies showed better responses]
Highlights the potential of lifileucel in real-world settings for melanoma treatment

Abstract

Background: Lifileucel is a tumor-derived autologous T-cell therapy approved by the US FDA for the treatment of patients with advanced (unresectable or metastatic) melanoma previously treated with an immune checkpoint inhibitor and, if BRAF V600-mutated, a BRAF ± MEK inhibitor. The benefit of commercial lifileucel has not yet been investigated in a real-world clinical setting. We report the first multicenter experience of lifileucel in patients with advanced melanoma.

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper

Cite This Study

Karapetyan et al. (Thu,) studied this question.

synapsesocial.com/papers/69e9b71b85696592c86eb18f https://doi.org/https://doi.org/10.1016/j.ejcskn.2026.100897

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark

View Full Paper